[go: up one dir, main page]

KR960700752A - 광범위한 종양억제 유전자와 유전자 생성물 그리고 종양억제 유전자 요법의 방법 - Google Patents

광범위한 종양억제 유전자와 유전자 생성물 그리고 종양억제 유전자 요법의 방법

Info

Publication number
KR960700752A
KR960700752A KR1019950704162A KR19950704162A KR960700752A KR 960700752 A KR960700752 A KR 960700752A KR 1019950704162 A KR1019950704162 A KR 1019950704162A KR 19950704162 A KR19950704162 A KR 19950704162A KR 960700752 A KR960700752 A KR 960700752A
Authority
KR
South Korea
Prior art keywords
tumor suppressor
methods
extensive
gene therapy
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019950704162A
Other languages
English (en)
Other versions
KR100326136B1 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR960700752A publication Critical patent/KR960700752A/ko
Application granted granted Critical
Publication of KR100326136B1 publication Critical patent/KR100326136B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1019950704162A 1993-03-25 1994-03-24 광범위한종양억제유전자와유전자생성물그리고종양억제유전자요법의방법 Expired - Fee Related KR100326136B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/038,760 US5496731A (en) 1993-03-25 1993-03-25 Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US038760 1993-03-25
PCT/US1994/003211 WO1994021115A1 (en) 1993-03-25 1994-03-24 Broad spectrum tumor suppressor genes, gene products and methods for tumor suppression gene therapy

Publications (2)

Publication Number Publication Date
KR960700752A true KR960700752A (ko) 1996-02-24
KR100326136B1 KR100326136B1 (ko) 2002-11-23

Family

ID=21901738

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950704162A Expired - Fee Related KR100326136B1 (ko) 1993-03-25 1994-03-24 광범위한종양억제유전자와유전자생성물그리고종양억제유전자요법의방법

Country Status (9)

Country Link
US (2) US5496731A (ko)
EP (1) EP0693874A4 (ko)
JP (1) JP3739787B2 (ko)
KR (1) KR100326136B1 (ko)
AU (1) AU697446B2 (ko)
CA (1) CA2159085A1 (ko)
IL (1) IL109092A (ko)
TW (1) TW379227B (ko)
WO (1) WO1994021115A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980077401A (ko) * 1997-04-18 1998-11-16 문우철 와일드타입 p53 유전자벡터와 양이온성 리포솜을 함유하는 암의 유전자 치료제

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105156B1 (en) * 1987-09-17 2006-09-12 The Regents Of The University Of California Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells
CA2042093C (en) * 1990-05-09 2002-12-24 Gyula Hadlaczky Cell line carrying an excess of mammalian centromeres
US5641484A (en) * 1990-12-04 1997-06-24 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5643567A (en) * 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
ES2093248T3 (es) * 1990-12-04 1996-12-16 Univ Texas Metodos y composiciones para la supresion de la transformacion mediada por el neu.
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
AU663702B2 (en) 1991-03-06 1995-10-19 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
AU7404994A (en) * 1993-07-30 1995-02-28 Regents Of The University Of California, The Endocardial infusion catheter
US20030060435A1 (en) * 1994-05-31 2003-03-27 Serge Carillo Method of cancer treatment by p53 protein control
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US5939401A (en) * 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US6331524B1 (en) * 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6794185B1 (en) 1995-03-29 2004-09-21 Millennium Pharmaceuticals, Inc. fohy030 nucleic acid molecules
US6251597B1 (en) 1996-03-29 2001-06-26 Millennium Pharmaceuticals, Inc. Methods for detecting fohy030
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
US6825320B1 (en) 1995-03-29 2004-11-30 Millenium Pharmaceuticals, Inc. FOHY03 polypeptides
US5869040A (en) * 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
ES2204980T3 (es) * 1995-06-30 2004-05-01 Takara Bio Inc. Nuevo promotor y metodo de expresion de genes que lo utiliza.
US5770720A (en) * 1995-08-30 1998-06-23 Barnes-Jewish Hospital Ubiquitin conjugating enzymes having transcriptional repressor activity
ES2264145T3 (es) * 1995-11-30 2006-12-16 The Board Of Regents, The University Of Texas System Metodos y composiciones para el tratamiento de cancer.
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
EP0894139A1 (en) 1996-03-20 1999-02-03 Board Of Regents The University Of Texas System Sensitization of her-2/neu overexpressing cancer cells to chemotherapy
US6312909B1 (en) 1996-03-29 2001-11-06 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis prevention and treatment of tumor progression
US20030033617A1 (en) * 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6025155A (en) * 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6077697A (en) * 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
EP0975750A2 (en) * 1997-02-20 2000-02-02 Board of Regents, The University of Texas System Modified retinoblastoma tumor suppressor proteins
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression
DE19882435B4 (de) 1997-06-02 2007-09-20 Thomas Jefferson University Verfahren zur Hemmung von Krebszellwachstum mit einem pRb2/p130 exprimierenden Vektor
AU8569698A (en) * 1997-07-11 1999-02-08 Brandeis University Method of inducing apoptosis by reducing the level of thiamin
WO1999002190A1 (en) * 1997-07-11 1999-01-21 Genzyme Corporation Organ-specific targeting of cationic amphiphile/retinoblastoma encoding dna complexes for gene therapy
CA2301333C (en) 1997-08-21 2011-12-06 Thomas Jefferson University Prb2/p130 peptide inhibitors of cdk2 kinase activity
US6372720B1 (en) 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
US6648552B1 (en) * 1999-10-14 2003-11-18 Bechtel Bwxt Idaho, Llc Sensor system for buried waste containment sites
US6841362B1 (en) 2000-02-29 2005-01-11 The Trustees Of Columbia University In The City Of New York Melanoma differentiation associated gene-7 promoter and uses thereof
US7229822B1 (en) * 2000-02-29 2007-06-12 Univ Columbia Melanoma differentation associated gene-5 and vectors and cells containing same
ATE463560T1 (de) * 2000-09-28 2010-04-15 Bioriginal Food & Science Corp Fad4, fad5, fad5-2, and fad6, mitglieder der fettsäuredesaturasefamilie und ihre verwendungen
AU2002312410A1 (en) * 2001-06-08 2002-12-23 Target Protein Technologies, Inc. Tissue-specific endothelial membrane proteins
CA2528136A1 (en) * 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
CN1851455B (zh) * 2005-04-22 2010-11-10 复旦大学附属中山医院 一种肿瘤标志物-血清蛋白指纹图谱的检测方法
US7470670B2 (en) * 2006-10-17 2008-12-30 Sbarro Health Research Organization, Inc. Peptide inhibitors of cyclin-dependent kinase activity and uses thereof
US20090054333A1 (en) * 2006-10-17 2009-02-26 Antonio Giordano Peptide inhibitors of cyclin-dependent kinase activity and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
CA1341576C (en) * 1986-08-11 2008-07-08 Thaddeus P. Dryja Diagnosis of retinoblastoma
GB8712646D0 (en) * 1987-05-29 1987-07-01 Clayton Found Res Structural evidence
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
US4942123A (en) * 1987-09-17 1990-07-17 The Regents Of The University Of California ppRB110 -phosphoprotein the retinoblastoma susceptibility gene product
DE68928728T2 (de) * 1988-01-21 1998-12-10 Massachusetts Eye & Ear Infirmary, Boston, Mass. Diagnose von retinoblastoma
CA2001815C (en) * 1988-10-31 2002-09-03 Wen-Hwa Lee Products and methods for controlling the suppression of the neoplastic phenotype
CA2014473A1 (en) * 1989-04-14 1990-10-14 Hong-Ji Xu Purified, highly specific antibodies against gene products including retinoblastoma and method
IE20010427A1 (en) * 1990-04-10 2003-03-05 Canji Inc Gene therapy for cell proliferative diseases
WO1992005272A1 (en) * 1990-09-17 1992-04-02 The Regents Of The University Of California Method and composition for controlling proliferation of cells
WO1992022640A1 (en) * 1991-06-10 1992-12-23 Research Development Foundation Rb TRANSFERRED CELLS AND METHOD

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980077401A (ko) * 1997-04-18 1998-11-16 문우철 와일드타입 p53 유전자벡터와 양이온성 리포솜을 함유하는 암의 유전자 치료제

Also Published As

Publication number Publication date
EP0693874A4 (en) 1997-06-25
KR100326136B1 (ko) 2002-11-23
WO1994021115A1 (en) 1994-09-29
JPH08508166A (ja) 1996-09-03
AU6415494A (en) 1994-10-11
EP0693874A1 (en) 1996-01-31
CA2159085A1 (en) 1994-09-29
US5912236A (en) 1999-06-15
JP3739787B2 (ja) 2006-01-25
US5496731A (en) 1996-03-05
AU697446B2 (en) 1998-10-08
IL109092A0 (en) 1994-06-24
TW379227B (en) 2000-01-11
IL109092A (en) 2005-09-25

Similar Documents

Publication Publication Date Title
KR960700752A (ko) 광범위한 종양억제 유전자와 유전자 생성물 그리고 종양억제 유전자 요법의 방법
FI953812A7 (fi) Kohdistettujen geenien säädelty transkriptio ja muita biologisia toimintoja
DE69735643D1 (de) IL12 zur Gentherapie der Tumoren
NO943344L (no) MN-gen og -protein
EE9900357A (et) Geenisekvenaator ja meetodid
AU4528493A (en) In vivo gene therapy with intron-free sequence of interest
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
AU3000297A (en) Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
AU5669494A (en) Human homolog of the e-cadherin gene and methods based thereon
HUP0004326A3 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
PL327628A1 (en) Method of fighting against the expression of gene cd 44 for therapeutic purposes
FR2736915B1 (fr) Variants de la proteine p53 et utilisations therapeutiques
AU6819194A (en) Isolated dna elements that direct pistil-specific and anther-specific gene expression and methods of using same
AU1536392A (en) Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes
AU5300396A (en) Radiation enhanced gene therapy for treatment of tumors
AU6282896A (en) Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins
AU5847194A (en) Novel entomopoxvirus genes, proteins and methods of use thereof
AU659462B2 (en) Methods for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegalovirus
ZA93212B (en) Enzyme castration of animal and tumor treatment
AU9247698A (en) Method for the identification of essential genes and therapeutic targets
DE69427290D1 (de) Verfahren zur induktion des todes von tumorzellen
FI962558L (fi) Uusi kasvainsuppressorigeeni
AU4644297A (en) Reversal of cancer phenotype by inhibiting expression of prostate tumor inducing gene
GB9217998D0 (en) Methods of treating cancer
DE69301018D1 (de) Menschliches Glycosyltransferase Gen

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20060210

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20070216

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20070216